Successful mobilization of peripheral blood stem cells (PBSCs) with AMD3100 in patients failing to collect with hematopoietic growth factors (HGF) and/or chemotherapy

Fassas, A.; Fox, M.; Calandra, Gary B.; Tricot, Guido

doi:10.1200/jco.2004.22.90140.6643

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AMD3100 trials have generally excluded patients who could not mobilize or collect sufficient cells for transplant (poor mobilizers), with the exception of two early phase 2 AMD3100 trials: AMD3100-2101 10 and AMD3100-2102. 15 In the study AMD3100-2101, 9/25 patients failed mobilization with G-CSF alone but proceeded to collect a transplantable dose of CD34 þ cells when remobilized with AMD3100 plus G-CSF. Obtaining cells for transplant from poor mobilizers is a significant medical need and the results from trials AMD3100-2101 and 2102 led to the conclusion that the drug should be made available to these patients via a Single Patient Use (SPU) protocol.…”

Section: Introductionmentioning

confidence: 99%

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

Calandra¹,

McCarty

McGuirk

et al. 2007

Bone Marrow Transplant

263

245

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

Calandra¹,

McCarty

McGuirk

et al. 2007

Bone Marrow Transplant

263

245

View full text Add to dashboard Cite

Role of CXCR4 Chemokine Receptor Blockade Using AMD3100 for Mobilization of Autologous Hematopoietic Progenitor Cells

Flomenberg

DiPersio

Calandra³

2005

Acta Haematol

View full text Add to dashboard Cite

G-CSF mobilization of hematopoietic progenitor cells (HPCs) is mediated through enzyme release from maturing myeloid cells, leading to digestion of adhesion molecules, trophic chemokines and their receptors, and the extracellular matrix. HPCs traffic to and are retained in the marrow through the trophic effects of the chemo kine SDF-1α/CXCL12 binding to its receptor, CXCR4. AMD3100 reversibly inhibits SDF-1α/CXCR4 binding, and AMD3100 administration mobilizes CD34+ cells into the circulation. AMD3100 has been tested in several clinical trials which demonstrate that it improves the number of CD34+ cells mobilized including patients failing to mobilize with G-CSF alone. Engraftment of AMD3100-mobilized cells is prompt and durable. Toxicities are mild and infrequent. Lymphoma and myeloma cells do not appear to be mobilized. AMD3100 appears to be a promising agent for HPC mobilization.

show abstract

Successful mobilization of peripheral blood stem cells (PBSCs) with AMD3100 in patients failing to collect with hematopoietic growth factors (HGF) and/or chemotherapy

Cited by 2 publications

References 0 publications

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

Role of CXCR4 Chemokine Receptor Blockade Using AMD3100 for Mobilization of Autologous Hematopoietic Progenitor Cells

Contact Info

Product

Resources

About